Royalty Pharma (RPRX) Stock Forecast, Price Target & Predictions
RPRX Stock Forecast
Royalty Pharma stock forecast is as follows: an average price target of $51.00 (represents a 104.65% upside from RPRX’s last price of $24.92) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
RPRX Price Target
The average price target for Royalty Pharma (RPRX) is $51.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $51.00 to $51.00. This represents a potential 104.65% upside from RPRX's last price of $24.92.
RPRX Analyst Ratings
According to 6 Wall Street analysts, Royalty Pharma's rating consensus is 'Buy'. The analyst rating breakdown for RPRX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Royalty Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Chris Shibutani | Goldman Sachs | $51.00 | $29.16 | 74.93% | 104.65% |
| Jul 11, 2024 | Terence Flynn | Morgan Stanley | $51.00 | $25.73 | 98.21% | 104.65% |
| Jun 07, 2024 | Chris Shibutani | Goldman Sachs | $50.00 | $27.09 | 84.57% | 100.64% |
| Jun 03, 2024 | Ashwani Verma | UBS | $28.00 | $27.35 | 2.38% | 12.36% |
| Dec 06, 2022 | Morgan Stanley | $51.00 | $42.87 | 18.96% | 104.65% | |
| Jun 13, 2022 | Ashwani Verma | UBS | $47.00 | $38.46 | 22.20% | 88.60% |
The latest Royalty Pharma stock forecast, released on Sep 04, 2024 by Chris Shibutani from Goldman Sachs, set a price target of $51.00, which represents a 74.93% increase from the stock price at the time of the forecast ($29.16), and a 104.65% increase from RPRX last price ($24.92).
Royalty Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $45.00 |
| Last Closing Price | $24.92 | $24.92 | $24.92 |
| Upside/Downside | -100.00% | -100.00% | 80.58% |
In the current month, the average price target of Royalty Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Royalty Pharma's last price of $24.92. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Aug 13, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Jul 11, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jun 12, 2024 | Johnson Rice | Overweight | Overweight | Hold |
| Jun 12, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jun 07, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Jun 03, 2024 | UBS | Buy | Neutral | Downgrade |
| May 23, 2024 | Needham | Buy | Buy | Hold |
| May 17, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Dec 06, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Jun 13, 2022 | UBS | Buy | Initialise | |
| Apr 27, 2022 | Goldman Sachs | Buy | Initialise |
Royalty Pharma's last stock rating was published by Goldman Sachs on Sep 04, 2024. The company gave RPRX a "Buy" rating, the same as its previous rate.
Royalty Pharma Financial Forecast
Royalty Pharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $536.31M | $538.20M | $683.97M | $565.75M | $573.46M | $535.96M | $562.05M | $575.70M | $585.77M | $554.96M | $573.03M | $572.14M | $538.40M | $507.62M |
| Avg Forecast | $853.00M | $747.61M | $684.46M | $719.02M | $614.83M | $696.92M | $627.42M | $665.57M | $685.52M | $631.74M | $543.70M | $902.02M | $1.06B | $586.32M | $528.36M | $597.01M | $552.06M | $563.10M | $484.33M | $511.72M | $483.97M | $451.66M | $468.93M |
| High Forecast | $918.02M | $804.59M | $736.63M | $773.82M | $624.42M | $705.08M | $627.42M | $665.57M | $708.87M | $659.14M | $585.14M | $970.78M | $1.15B | $586.32M | $528.36M | $597.01M | $552.06M | $563.10M | $484.33M | $511.72M | $483.97M | $451.66M | $468.93M |
| Low Forecast | $746.62M | $654.37M | $599.10M | $629.35M | $605.25M | $688.75M | $627.42M | $665.57M | $662.16M | $615.78M | $475.89M | $789.53M | $931.36M | $586.32M | $528.36M | $597.01M | $552.06M | $563.10M | $484.33M | $511.72M | $483.97M | $451.66M | $468.93M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.85% | 0.99% | 0.76% | 0.53% | 0.98% | 1.01% | 0.94% | 1.04% | 1.04% | 1.15% | 1.12% | 1.18% | 1.19% | 1.08% |
Royalty Pharma's average Quarter revenue forecast for Dec 23 based on 2 analysts is $685.52M, with a low forecast of $662.16M, and a high forecast of $708.87M. RPRX's average Quarter revenue forecast represents a 27.82% increase compared to the company's last Quarter revenue of $536.31M (Sep 23).
Royalty Pharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | $167.95M | $248.84M | $527.47M | $169.00M | $192.19M | $388.41M | $233.56M | $60.67M | $152.05M | $483.94M | $112.20M | $208.94M | $322.08M | $482.00M |
| Avg Forecast | $621.82M | $544.99M | $498.96M | $524.15M | $448.20M | $508.04M | $457.38M | $148.95M | $499.73M | $460.53M | $396.34M | $135.41M | $65.90M | $423.03M | $381.21M | $123.10M | $398.31M | $406.27M | $349.44M | $174.00M | $349.18M | $325.86M | $387.18M |
| High Forecast | $669.22M | $586.53M | $536.99M | $564.10M | $455.19M | $513.99M | $457.38M | $178.74M | $516.76M | $480.50M | $426.55M | $162.50M | $79.08M | $423.03M | $381.21M | $147.72M | $398.31M | $406.27M | $349.44M | $208.80M | $349.18M | $325.86M | $464.61M |
| Low Forecast | $544.27M | $477.03M | $436.73M | $458.78M | $441.22M | $502.09M | $457.38M | $119.16M | $482.70M | $448.90M | $346.92M | $108.33M | $52.72M | $423.03M | $381.21M | $98.48M | $398.31M | $406.27M | $349.44M | $139.20M | $349.18M | $325.86M | $309.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.36% | 0.63% | 3.90% | 2.56% | 0.45% | 1.02% | 1.90% | 0.15% | 0.37% | 1.38% | 0.64% | 0.60% | 0.99% | 1.24% |
2 analysts predict RPRX's average Quarter EBITDA for Dec 23 to be $499.73M, with a high of $516.76M and a low of $482.70M. This is 197.55% upper than Royalty Pharma's previous annual EBITDA (Sep 23) of $167.95M.
Royalty Pharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | $72.11M | $227.63M | $340.75M | $-610.17M | $217.83M | $304.50M | $-39.87M | $6.70M | $101.93M | $440.78M | $69.12M | $171.09M | $290.63M | $442.07M |
| Avg Forecast | $806.11M | $628.29M | $653.97M | $624.34M | $583.81M | $549.75M | $572.16M | $73.78M | $598.67M | $456.13M | $491.96M | $67.08M | $8.58M | $423.28M | $466.25M | $60.98M | $462.84M | $418.12M | $419.64M | $107.19M | $420.82M | $352.82M | $355.11M |
| High Forecast | $885.98M | $690.54M | $718.78M | $681.63M | $599.44M | $557.31M | $572.25M | $88.54M | $604.60M | $509.44M | $540.71M | $80.49M | $10.30M | $423.28M | $466.25M | $73.17M | $462.84M | $418.12M | $419.64M | $128.63M | $420.82M | $352.82M | $426.13M |
| Low Forecast | $675.42M | $526.43M | $547.95M | $592.73M | $568.17M | $542.20M | $572.08M | $59.03M | $592.74M | $402.81M | $412.21M | $53.66M | $6.87M | $423.28M | $466.25M | $48.78M | $462.84M | $418.12M | $419.64M | $85.75M | $420.82M | $352.82M | $284.09M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.16% | 0.46% | 5.08% | -71.08% | 0.51% | 0.65% | -0.65% | 0.01% | 0.24% | 1.05% | 0.64% | 0.41% | 0.82% | 1.24% |
Royalty Pharma's average Quarter net income forecast for Dec 23 is $598.67M, with a range of $592.74M to $604.60M. RPRX's average Quarter net income forecast represents a 730.17% increase compared to the company's last Quarter net income of $72.11M (Sep 23).
Royalty Pharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | $57.23M | $47.63M | $85.69M | $73.23M | $50.69M | $51.84M | $51.54M | $46.16M | $48.59M | $44.92M | $43.16M | $250.31M | $22.74M | $92.50M |
| Avg Forecast | $73.41M | $64.34M | $58.91M | $61.88M | $52.91M | $59.98M | $54.00M | $73.47M | $59.00M | $54.37M | $46.79M | $66.79M | $50.13M | $50.46M | $45.47M | $60.72M | $47.51M | $48.46M | $41.68M | $66.92M | $41.65M | $38.87M | $74.30M |
| High Forecast | $79.01M | $69.24M | $63.40M | $66.60M | $53.74M | $60.68M | $54.00M | $88.16M | $61.01M | $56.73M | $50.36M | $80.15M | $60.16M | $50.46M | $45.47M | $72.86M | $47.51M | $48.46M | $41.68M | $80.31M | $41.65M | $38.87M | $89.16M |
| Low Forecast | $64.26M | $56.32M | $51.56M | $54.16M | $52.09M | $59.28M | $54.00M | $58.78M | $56.99M | $53.00M | $40.96M | $53.43M | $40.11M | $50.46M | $45.47M | $48.57M | $47.51M | $48.46M | $41.68M | $53.54M | $41.65M | $38.87M | $59.44M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.05% | 1.02% | 1.28% | 1.46% | 1.00% | 1.14% | 0.85% | 0.97% | 1.00% | 1.08% | 0.64% | 6.01% | 0.58% | 1.24% |
Royalty Pharma's average Quarter SG&A projection for Dec 23 is $59.00M, based on 2 Wall Street analysts, with a range of $56.99M to $61.01M. The forecast indicates a 3.08% rise compared to RPRX last annual SG&A of $57.23M (Sep 23).
Royalty Pharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | $0.16 | $0.51 | $0.76 | $-1.39 | $0.50 | $0.70 | $-0.09 | $0.02 | $0.24 | $1.08 | $0.18 | $0.44 | $0.79 | $0.09 |
| Avg Forecast | $1.36 | $1.06 | $1.10 | $1.05 | $0.98 | $0.93 | $0.97 | $0.99 | $1.01 | $0.77 | $0.83 | $1.27 | $1.47 | $0.71 | $0.78 | $0.73 | $0.78 | $0.70 | $0.70 | $0.66 | $0.70 | $0.59 | $0.61 |
| High Forecast | $1.49 | $1.17 | $1.21 | $1.15 | $1.01 | $0.94 | $0.97 | $0.99 | $1.02 | $0.86 | $0.91 | $1.40 | $1.62 | $0.71 | $0.78 | $0.73 | $0.78 | $0.70 | $0.70 | $0.66 | $0.70 | $0.59 | $0.61 |
| Low Forecast | $1.14 | $0.89 | $0.92 | $1.00 | $0.96 | $0.91 | $0.97 | $0.99 | $1.00 | $0.68 | $0.70 | $1.07 | $1.23 | $0.71 | $0.78 | $0.73 | $0.78 | $0.70 | $0.70 | $0.66 | $0.70 | $0.59 | $0.61 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.21% | 0.61% | 0.60% | -0.94% | 0.71% | 0.90% | -0.13% | 0.02% | 0.34% | 1.54% | 0.27% | 0.62% | 1.33% | 0.15% |
According to 2 Wall Street analysts, Royalty Pharma's projected average Quarter EPS for Dec 23 is $1.01, with a low estimate of $1.00 and a high estimate of $1.02. This represents a 531.27% increase compared to RPRX previous annual EPS of $0.16 (Sep 23).
Royalty Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CVAC | CureVac | $2.95 | $29.00 | 883.05% | Buy |
| PRME | Prime Medicine | $2.91 | $17.25 | 492.78% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| RPRX | Royalty Pharma | $25.12 | $51.00 | 103.03% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| ADPT | Adaptive Bio | $6.52 | $12.33 | 89.11% | Hold |
| AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
| IOVA | Iovance Biotherapeutics | $7.81 | $12.40 | 58.77% | Buy |
| ASND | Ascendis Pharma | $140.30 | $211.14 | 50.49% | Buy |
| BGNE | BeiGene | $179.06 | $267.33 | 49.30% | Buy |
| BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |
| MDGL | Madrigal Pharmaceuticals | $306.08 | $315.75 | 3.16% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |
| DNA | Ginkgo Bioworks | $9.61 | $7.00 | -27.16% | Buy |